XTL Biopharmaceuticals Ltd.

DB:H2K2 Stock Report

Market Cap: €12.4m

XTL Biopharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of H2K2?
Owner TypeNumber of SharesOwnership Percentage
Institutions26,784,6004.92%
Individual Insiders131,648,19624.2%
General Public386,473,35370.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 9 shareholders own 29.08% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
23.5%
Alexander Rabinowitch
128,288,887€2.9m0%no data
3.65%
Noked Capital Ltd.
19,888,800€451.9k0%0.08%
0.72%
Morgan Stanley, Investment Banking and Brokerage Investments
3,917,100€89.0k-1.51%no data
0.55%
Shlomo Shalev
3,019,309€68.6k0%no data
0.25%
Citadel Advisors LLC
1,363,100€31.0k0%no data
0.16%
Geode Capital Management, LLC
890,200€20.2k2.03%no data
0.13%
UBS Asset Management AG
695,400€15.8k12,800%no data
0.062%
Doron Turgeman
340,000€7.7k0%no data
0.0055%
BNP Paribas Arbitrage Sa, Asset Management Arm
30,000€682.20%no data
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.